ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Mechanism of
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo investigate the role of the SREBP-1/SCD1 pathway in mediating the protective effect of
methodsFourteen SD rats were gavaged with TXYF for 7 consecutive days to prepare TXYF-medicated serum. BRL 3A cells in routine culture were examined for changes in cell viability using CCK-8 assay following treatment with different concentrations of 5-HT. In BRL 3A cells treated with 5-HT and different concentrations of the medicated serum, SOD, MDA, and ROS levels were measured, and mitochondrial membrane potential and cell morphology were evaluated using JC-1 staining and electron microscopy; autophagosomes and LC3B expression were detected with immunofluorescence staining, and the protein expression levels of Cyt-c, caspase-3, Gsk3β, Beclin-1, LC3 I/II, p62, SREBP-1, SCD1, and 5-HT
resultsThe optimal 5-HT concentration for modeling was 1.5 mmol/L. In 5-HT-treated cells, treatment with TXYF-medicated serum significantly reduced cellular ROS and MDA levels, increased SOD activities, lowered mitochondrial membrane potential, and alleviated mitochondrial swelling. The cells treated with TXYF-medicated serum also showed decreased expression levels of LC3B, MDC, Beclin-1, LC3 II/LC3 I, Cyt-c, SCD1 and 5-HT
conclusionsTXYF-medicated serum alleviate oxidative stress and autophagy dysfunction via the SREBP-1/SCD1 pathway to protect BRL 3A cells against 5-HT-induced injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.